Literature DB >> 21740919

The role of 5-HT₁A receptors in fish oil-mediated increased BDNF expression in the rat hippocampus and cortex: a possible antidepressant mechanism.

Aparecida Vines1, Ana Marcia Delattre, Marcelo M S Lima, Laís Soares Rodrigues, Deborah Suchecki, Ricardo B Machado, Sergio Tufik, Sofia I R Pereira, Sílvio M Zanata, Anete Curte Ferraz.   

Abstract

Epidemiological and dietary studies show that nutritional deficit of omega-3 polyunsaturated fatty acids (ω-3 PUFA) is directly related to the prevalence and severity of depression. Supplementation with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) during critical periods of development (pregnancy and lactation) is essential for cortical maturation, synaptogenesis and myelination, and may also mitigate the risk for cognitive deficits and psychopathologies in young adults. The present study was performed to evaluate the involvement of serotonin (5-HT) receptors, particularly of 5-HT(1A), and hippocampal brain-derived neurotrophic factor (BDNF) expression in the antidepressant effect of ω-3 PUFA supplementation. In Experiment 1, the antidepressant effects of fish oil were assessed by the modified forced swim test in adult rats. The data indicated a robust antidepressant effect produced by this supplementation and that treatment of the rats with WAY 100135 reversed this effect. In Experiment 2, cortical and hippocampal contents of BDNF, 5-HT, dopamine (DA) and its metabolites, 5-hydroxyindoleacetic acid (5-HIAA), and 3,4-dihydroxyphenylacetic acid (DOPAC), were determined in animals subjected to the same protocol. Increased BDNF expression in the cortex and hippocampus of both age groups was detected. In 90 day-old rats, 5-HT content in the hippocampus was increased, whereas 5-HIAA formation was diminished in the fish oil group. We suggest the occurrence of a reciprocal involvement of 5-HT(1A) receptors activation and the hippocampal BDNF-increased expression mediated by fish oil supplementation. These data corroborate and expand the notion that supplementation with ω-3 PUFA produces antidepressant effects mediated by an increase in serotonergic neurotransmission, particularly in the hippocampus. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740919     DOI: 10.1016/j.neuropharm.2011.06.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  36 in total

1.  The activation of supraspinal GPR40/FFA1 receptor signalling regulates the descending pain control system.

Authors:  K Nakamoto; T Nishinaka; N Sato; F Aizawa; T Yamashita; M Mankura; Y Koyama; F Kasuya; S Tokuyama
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Deep brain stimulation reverses anhedonic-like behavior in a chronic model of depression: role of serotonin and brain derived neurotrophic factor.

Authors:  Clement Hamani; Danilo C Machado; Débora C Hipólide; Francisco P Dubiela; Deborah Suchecki; Carlos E Macedo; Fabio Tescarollo; Uilton Martins; Luciene Covolan; José N Nobrega
Journal:  Biol Psychiatry       Date:  2011-10-14       Impact factor: 13.382

3.  Cross-Generational trans Fat Consumption Favors Self-Administration of Amphetamine and Changes Molecular Expressions of BDNF, DAT, and D1/D2 Receptors in the Cortex and Hippocampus of Rats.

Authors:  Fábio Teixeira Kuhn; Verônica Tironi Dias; Karine Roversi; Luciana Taschetto Vey; Daniele Leão de Freitas; Camila Simonetti Pase; Katiane Roversi; Juliana Cristina Veit; Tatiana Emanuelli; Marilise Escobar Bürger
Journal:  Neurotox Res       Date:  2015-07-19       Impact factor: 3.911

4.  Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum.

Authors:  Neha Milind Chitre; Bo Jarrett Wood; Azizi Ray; Nader H Moniri; Kevin Sean Murnane
Journal:  Neuropharmacology       Date:  2020-01-27       Impact factor: 5.250

5.  Maternal Omega-3 Supplement Improves Dopaminergic System in Pre- and Postnatal Inflammation-Induced Neurotoxicity in Parkinson's Disease Model.

Authors:  Ana Marcia Delattre; Bruno Carabelli; Marco Aurélio Mori; Paula G Kempe; Luiz E Rizzo de Souza; Silvio M Zanata; Ricardo B Machado; Deborah Suchecki; Belmira L S Andrade da Costa; Marcelo M S Lima; Anete C Ferraz
Journal:  Mol Neurobiol       Date:  2016-02-29       Impact factor: 5.590

6.  Adult emotionality and neural plasticity as a function of adolescent nutrient supplementation in male rats.

Authors:  Nora McCall; Darshini Mahadevia; Jennifer A Corriveau; Melissa J Glenn
Journal:  Pharmacol Biochem Behav       Date:  2015-03-14       Impact factor: 3.533

7.  Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson's disease.

Authors:  K M Denny Joseph
Journal:  Neurochem Res       Date:  2015-02-17       Impact factor: 3.996

8.  The Antidepressant-Like Effect of Fish Oil: Possible Role of Ventral Hippocampal 5-HT1A Post-synaptic Receptor.

Authors:  Bruno Carabelli; Ana Marcia Delattre; Claudia Pudell; Marco Aurélio Mori; Deborah Suchecki; Ricardo B Machado; Daniel Paulino Venancio; Sílvia Regina Piazzetta; Ivilim Hammerschmidt; Sílvio M Zanata; Marcelo M S Lima; Janaína Menezes Zanoveli; Anete Curte Ferraz
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

9.  Role of Omega-3 Fatty Acids in the Etiology, Treatment, and Prevention of Depression: Current Status and Future Directions.

Authors:  Robert K McNamara
Journal:  J Nutr Intermed Metab       Date:  2016-05-04

10.  Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression.

Authors:  Jessica A Able; Yanhong Liu; Ronald Jandacek; Therese Rider; Patrick Tso; Robert K McNamara
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.